WillemzeR. New concepts in the classification of cutaneous lymphomas. Arch Dermatol1995; 131:1077–1080.
2.
KimYHHoppeRT. Mycosis fungoides and the Sézary syndrome. Semin Oncol1999; 26:276–289.
3.
ZackheimHSAminSKashani–SabetM. Prognosis in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patients. J Am Acad Dermatol1999; 40:418–125.
4.
JackowCMCatherJCHearneV. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor Vβ gene expansion. Blood1997; 89:32–40.
5.
VonderheidECBernengoMGBurgG. Update on erythrodermic cutaneous T-cell lymphoma: Report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol2002; 46:95–106.
6.
EdelsonRBergerCGasparroF. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med1987; 316:297–303.
HealdPRookAPerezM. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol1992; 27:427–433.
9.
KohHKDavisBEMeolaT. Extracorporeal photopheresis for the treatment of 34 patients with cutaneous T cell lymphoma (CTCL). J Invest Dermatol1994; 102:567 [abstr].
10.
ZicJAStricklandGPGreerJP. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol1996; 35:935–945.
11.
GottliebSLWolfeJTFoxFE. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: A 10-year experience at a single institution. J Am Acad Dermatol1996; 35:946–957.
12.
DuvicMHesterJPLemakNA. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol1996; 35:573–579.
13.
VonderheidECZhangQLessinSR. Use of serum soluble interleukin-2 receptor levels to monitor patients with cutaneous T cell lymphoma. J Am Acad Dermatol1998; 38:207–220.
14.
JiangSBDietzSBKimM. Extracorporeal photochemotherapy for cutaneous T-cell lymphoma: A 9.7-year experience. Photodermatol Photoimmunol Photomed1999; 15:161–165.
15.
BisacciaEGonzalezJPalangioM. Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: A 9-year retrospective study at a single institution. J Am Acad Dermatol2000; 43:263–271.
16.
StevensSRBaronEDMastenS. Circulating CD4+CD7–lymphocyte burden and rapidity of response. Predictors of outcome in the treatment of Sézary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis. Arch Dermatol2002; 138:1347–1350.
17.
KnoblerEWarmuthICoccoC. Extracorporeal photochemotherapy—the Columbia Presbyterian experience. Photodermatol Photoimmunol Photomed2002; 18:232–327.
18.
BouwhuisSAel-AzharyRAGibsonLE. Effect of insulindependent diabetes mellitus on response to extracorporeal photopheresis in patients with Sézary syndrome. J Am Acad Dermatol2002; 47:63–67.
19.
KayeFJBunnPASteinbergSM. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med1989; 321:1784–1790.
20.
PrinzBBehrensWHolzleE. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma—the Düsseldorf and Munich experience. Arch Dermatol Res1995; 287:621–626.
21.
Di RenzoMRubegniPDe AloeG. Extracorporeal photochemotherapy restores Th1/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma. Immunology1997; 92:99–103.
22.
RookAHSuchinKRKaoDMF. Photopheresis: Clinical applications and mechanism of action. J Investig Dermatol Symp Proc1999; 4:85–90.
23.
GoldmanBDOhS-KDavisBE. Serum soluble interleukin 2 receptor levels in erythrodermic cutaneous T-cell lymphoma correlate with response to photopheresis-based treatment. Arch Dermatol1993; 129:1166–1170.
24.
KonstantinowABaldaB-R. Treatment of cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Eur Acad Dermatol Venereol1997; 9:111–117.
25.
DuvicM. Response rates in photopheresis therapy for cutaneous T cell lymphoma, [letter]. J Am Acad Dermatol1997; 37:288.
26.
TalpurRWardSApisarnthanaraxN. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol2002; 47:672–684.
27.
HaleyHRDavisDASamsWM. Durable loss of a malignant T-cell clone in a stage IV cutaneous T-cell lymphoma patient treated with high-dose interferon and photopheresis. J Am Acad Dermatol1999; 41:880–883.
28.
RookAHGottliebSLWolfeJT. Pathogenesis of cutaneous T-cell lymphoma: Implications for the use of recombinant cytokines and photopheresis. Clin Exp Immunol1997; 107(Suppl 1):16–20.
29.
MarksDIRockmanSPOziemskiMA. Mechanisms of lymphocytotoxicity induced by extracorporeal photochemotherapy for cutaneous T cell lymphoma. J Clin Invest1990; 86:2080–2085.
30.
VowelsBRCassinMBoufalMH. Extracorporeal photochemotherapy induces the production of tumor necrosis factor-α by monocytes: Implications for the treatment of cutaneous T-cell lymphoma and systemic sclerosis. J Invest Dermatol1992; 98:686–692.
31.
BergerCLHanlonDKanadaD. Transimmunization, a novel approach for tumor immunotherapy. Transfus Apheresis Sci2002;26:205–216.
32.
AdachiYAdamatsuHHorioT. The effect of antibiotics on the production of superantigen from Staphylococcus aureus isolated from atopic dermatitis. J Dermatol Sci2002; 28:76–83.
